Gallium-68 Neomannosylated Human Serum Albumin-Based PET/CT Lymphoscintigraphy for Sentinel Lymph Node Mapping in Non-small Cell Lung Cancer

Jae Seon Eo; Hyun Koo Kim; Sungeun Kim; Yun Sang Lee; Jae Min Jeong; Young Ho Choi

doi:10.1245/s10434-014-3986-x

Gallium-68 Neomannosylated Human Serum Albumin-Based PET/CT Lymphoscintigraphy for Sentinel Lymph Node Mapping in Non-small Cell Lung Cancer

Jae Seon Eo, Hyun Koo Kim, Sungeun Kim, Yun Sang Lee, Jae Min Jeong, Young Ho Choi

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Abstract

Purpose: To develop imaging of lymphatics with resolution greater than that of lymphoscintigraphy using technetium-99 m neomannosyl human serum albumin (^99mTc-MSA), we developed a Gallium-68 (⁶⁸Ga) MSA for positron emission tomography (PET). This study is the first clinical trial to evaluate the feasibility of sentinel node detection using this novel ⁶⁸Ga tracer for the management of non-small cell lung cancer.

Methods: We enrolled 34 patients (20 men, 14 women; mean age, 64.3 ± 10.4 years) who were candidates for lobectomy with mediastinal lymph node dissection for clinical stage I non-small cell lung cancer. ⁶⁸Ga-MSA was administered in one injection into the peritumoral region, and lymphoscintigraphy was performed by PET/CT just before surgery. All harvested lymph nodes were cut into 2 mm slices and were ultimately diagnosed using formalin-fixed and paraffin-embedded sections with hematoxylin and eosin staining.

Results: The sentinel nodes were well visualized by PET/CT imaging from 15 to 120 min, and especially within 60 min, after injection. In all patients (100 %), sentinel nodes could be identified on PET/CT. The number of sentinel nodes identified was 1.9 ± 0.9 (range 1–5) per patient. The maximum standardized uptake values were 2882.2 ± 2124.3 in the tumor and 82.5 ± 159.0 in the sentinel nodes. Eight of 34 patients (23.5 %) had metastases in 13 sentinel nodes. No false-negative sentinel nodes were detected in any of the eight patients with N1 or N2 disease (0 %).

Conclusions: ⁶⁸Ga-MSA appears to be a promising tracer for sentinel node identification in non-small cell lung cancer.

Original language	English
Pages (from-to)	636-641
Number of pages	6
Journal	Annals of Surgical Oncology
Volume	22
Issue number	2
DOIs	https://doi.org/10.1245/s10434-014-3986-x
Publication status	Published - 2015
Externally published	Yes

ASJC Scopus subject areas

Surgery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1245/s10434-014-3986-x

Cite this

@article{f33ef54a8550488babb7390e2e55f41e,

title = "Gallium-68 Neomannosylated Human Serum Albumin-Based PET/CT Lymphoscintigraphy for Sentinel Lymph Node Mapping in Non-small Cell Lung Cancer",

abstract = "Purpose: To develop imaging of lymphatics with resolution greater than that of lymphoscintigraphy using technetium-99 m neomannosyl human serum albumin (99mTc-MSA), we developed a Gallium-68 (68Ga) MSA for positron emission tomography (PET). This study is the first clinical trial to evaluate the feasibility of sentinel node detection using this novel 68Ga tracer for the management of non-small cell lung cancer.Methods: We enrolled 34 patients (20 men, 14 women; mean age, 64.3 ± 10.4 years) who were candidates for lobectomy with mediastinal lymph node dissection for clinical stage I non-small cell lung cancer. 68Ga-MSA was administered in one injection into the peritumoral region, and lymphoscintigraphy was performed by PET/CT just before surgery. All harvested lymph nodes were cut into 2 mm slices and were ultimately diagnosed using formalin-fixed and paraffin-embedded sections with hematoxylin and eosin staining.Results: The sentinel nodes were well visualized by PET/CT imaging from 15 to 120 min, and especially within 60 min, after injection. In all patients (100 %), sentinel nodes could be identified on PET/CT. The number of sentinel nodes identified was 1.9 ± 0.9 (range 1–5) per patient. The maximum standardized uptake values were 2882.2 ± 2124.3 in the tumor and 82.5 ± 159.0 in the sentinel nodes. Eight of 34 patients (23.5 %) had metastases in 13 sentinel nodes. No false-negative sentinel nodes were detected in any of the eight patients with N1 or N2 disease (0 %).Conclusions: 68Ga-MSA appears to be a promising tracer for sentinel node identification in non-small cell lung cancer.",

author = "Eo, {Jae Seon} and Kim, {Hyun Koo} and Sungeun Kim and Lee, {Yun Sang} and Jeong, {Jae Min} and Choi, {Young Ho}",

note = "Funding Information: This work was supported by a National Research Foundation of Korea (NRF) Grant funded by the Ministry of Education, Science and Technology (No: 2012012166) and by a Korea University Grant (K1132181). Publisher Copyright: {\textcopyright} 2014, Society of Surgical Oncology.",

year = "2015",

doi = "10.1245/s10434-014-3986-x",

language = "English",

volume = "22",

pages = "636--641",

journal = "Annals of Surgical Oncology",

issn = "1068-9265",

publisher = "Springer New York",

number = "2",

}

TY - JOUR

T1 - Gallium-68 Neomannosylated Human Serum Albumin-Based PET/CT Lymphoscintigraphy for Sentinel Lymph Node Mapping in Non-small Cell Lung Cancer

AU - Eo, Jae Seon

AU - Kim, Hyun Koo

AU - Kim, Sungeun

AU - Lee, Yun Sang

AU - Jeong, Jae Min

AU - Choi, Young Ho

N1 - Funding Information: This work was supported by a National Research Foundation of Korea (NRF) Grant funded by the Ministry of Education, Science and Technology (No: 2012012166) and by a Korea University Grant (K1132181). Publisher Copyright: © 2014, Society of Surgical Oncology.

PY - 2015

Y1 - 2015

N2 - Purpose: To develop imaging of lymphatics with resolution greater than that of lymphoscintigraphy using technetium-99 m neomannosyl human serum albumin (99mTc-MSA), we developed a Gallium-68 (68Ga) MSA for positron emission tomography (PET). This study is the first clinical trial to evaluate the feasibility of sentinel node detection using this novel 68Ga tracer for the management of non-small cell lung cancer.Methods: We enrolled 34 patients (20 men, 14 women; mean age, 64.3 ± 10.4 years) who were candidates for lobectomy with mediastinal lymph node dissection for clinical stage I non-small cell lung cancer. 68Ga-MSA was administered in one injection into the peritumoral region, and lymphoscintigraphy was performed by PET/CT just before surgery. All harvested lymph nodes were cut into 2 mm slices and were ultimately diagnosed using formalin-fixed and paraffin-embedded sections with hematoxylin and eosin staining.Results: The sentinel nodes were well visualized by PET/CT imaging from 15 to 120 min, and especially within 60 min, after injection. In all patients (100 %), sentinel nodes could be identified on PET/CT. The number of sentinel nodes identified was 1.9 ± 0.9 (range 1–5) per patient. The maximum standardized uptake values were 2882.2 ± 2124.3 in the tumor and 82.5 ± 159.0 in the sentinel nodes. Eight of 34 patients (23.5 %) had metastases in 13 sentinel nodes. No false-negative sentinel nodes were detected in any of the eight patients with N1 or N2 disease (0 %).Conclusions: 68Ga-MSA appears to be a promising tracer for sentinel node identification in non-small cell lung cancer.

AB - Purpose: To develop imaging of lymphatics with resolution greater than that of lymphoscintigraphy using technetium-99 m neomannosyl human serum albumin (99mTc-MSA), we developed a Gallium-68 (68Ga) MSA for positron emission tomography (PET). This study is the first clinical trial to evaluate the feasibility of sentinel node detection using this novel 68Ga tracer for the management of non-small cell lung cancer.Methods: We enrolled 34 patients (20 men, 14 women; mean age, 64.3 ± 10.4 years) who were candidates for lobectomy with mediastinal lymph node dissection for clinical stage I non-small cell lung cancer. 68Ga-MSA was administered in one injection into the peritumoral region, and lymphoscintigraphy was performed by PET/CT just before surgery. All harvested lymph nodes were cut into 2 mm slices and were ultimately diagnosed using formalin-fixed and paraffin-embedded sections with hematoxylin and eosin staining.Results: The sentinel nodes were well visualized by PET/CT imaging from 15 to 120 min, and especially within 60 min, after injection. In all patients (100 %), sentinel nodes could be identified on PET/CT. The number of sentinel nodes identified was 1.9 ± 0.9 (range 1–5) per patient. The maximum standardized uptake values were 2882.2 ± 2124.3 in the tumor and 82.5 ± 159.0 in the sentinel nodes. Eight of 34 patients (23.5 %) had metastases in 13 sentinel nodes. No false-negative sentinel nodes were detected in any of the eight patients with N1 or N2 disease (0 %).Conclusions: 68Ga-MSA appears to be a promising tracer for sentinel node identification in non-small cell lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=84921021721&partnerID=8YFLogxK

U2 - 10.1245/s10434-014-3986-x

DO - 10.1245/s10434-014-3986-x

M3 - Article

C2 - 25155392

AN - SCOPUS:84921021721

SN - 1068-9265

VL - 22

SP - 636

EP - 641

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

IS - 2

ER -

Gallium-68 Neomannosylated Human Serum Albumin-Based PET/CT Lymphoscintigraphy for Sentinel Lymph Node Mapping in Non-small Cell Lung Cancer

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this